Jefferies Financial Group Inc. Has $2.05 Million Stock Position in Collegium Pharmaceutical, Inc. $COLL

Posted by Brenda Bartman on May 28th, 2026

Jefferies Financial Group Inc. lowered its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 65.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 44,240 shares of the specialty pharmaceutical company’s stock after selling 82,325 shares during the period. Jefferies Financial Group Inc. owned about 0.14% of Collegium Pharmaceutical worth $2,048,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 17.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,174 shares of the specialty pharmaceutical company’s stock worth $193,000 after buying an additional 611 shares in the last quarter. LSV Asset Management increased its holdings in Collegium Pharmaceutical by 0.4% in the 4th quarter. LSV Asset Management now owns 347,900 shares of the specialty pharmaceutical company’s stock worth $16,108,000 after purchasing an additional 1,300 shares in the last quarter. ProShare Advisors LLC increased its holdings in Collegium Pharmaceutical by 5.0% in the 4th quarter. ProShare Advisors LLC now owns 7,507 shares of the specialty pharmaceutical company’s stock worth $348,000 after purchasing an additional 356 shares in the last quarter. HighTower Advisors LLC acquired a new position in Collegium Pharmaceutical in the 4th quarter worth about $281,000. Finally, Baader Bank Aktiengesellschaft acquired a new position in Collegium Pharmaceutical in the 4th quarter worth about $371,000.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the sale, the executive vice president owned 77,071 shares in the company, valued at approximately $2,691,319.32. The trade was a 15.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Scott Dreyer sold 49,976 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the sale, the executive vice president owned 71,770 shares in the company, valued at $2,900,225.70. This trade represents a 41.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.85% of the company’s stock.

Wall Street Analyst Weigh In

COLL has been the subject of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Weiss Ratings cut Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Truist Financial set a $58.00 target price on Collegium Pharmaceutical in a report on Tuesday, February 10th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Check Out Our Latest Report on Collegium Pharmaceutical

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $33.68 on Thursday. Collegium Pharmaceutical, Inc. has a 12-month low of $28.74 and a 12-month high of $50.79. The business has a 50-day simple moving average of $34.19 and a two-hundred day simple moving average of $41.50. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The stock has a market cap of $1.09 billion, a PE ratio of 16.51 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same quarter in the previous year, the company posted $1.49 EPS. The business’s revenue was up 8.9% on a year-over-year basis. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

(Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.